Ryan O'Reilly1,2,3, Sayako Yokoyama4,5, Justin Boyle6, Jeffrey C Kwong7,4,8,9,10,11, Allison McGeer7,12, Teresa To7,8,13, Beate Sander7,14,4,8,11. 1. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. ryan.oreilly@medportal.ca. 2. Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada. ryan.oreilly@medportal.ca. 3. , 200 Elizabeth Avenue, Eaton Building, Room 10-248, Toronto, ON, M5G 2C4, Canada. ryan.oreilly@medportal.ca. 4. Public Health Ontario, Toronto, ON, Canada. 5. University of Waterloo, Waterloo, ON, Canada. 6. Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. 7. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. 8. ICES, Toronto, ON, Canada. 9. Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada. 10. Centre for Vaccine-Preventable Diseases, University of Toronto, Toronto, ON, Canada. 11. University Health Network, Toronto, ON, Canada. 12. Sinai Health System, Toronto, ON, Canada. 13. The Hospital for Sick Children (SickKids), Toronto, ON, Canada. 14. Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada.
Abstract
PURPOSE: Streptococcus pneumoniae infections remain a significant source of morbidity and mortality worldwide. The purpose of this review was to summarize the impact of pneumococcal disease on health state utilities (HSU) in the acute phase of illness. METHODS: We searched MEDLINE, EMBASE, EconLit, the Health Technology Assessment Database, the National Health Economic Evaluation Database, and Tufts Cost-Effectiveness Registry (up to January 2020) for primary studies. Eligible studies elicited HSU estimates using preference-based instruments for the acute phase of infection of pneumococcal syndromes including acute otitis media, pneumonia/lower respiratory tract infections, bacteremia/sepsis, and meningitis. Two reviewers independently conducted screening, data extraction and quality appraisal. RESULTS: We screened 10,178 studies, of which 26 met our inclusion criteria. Cohort sizes ranged from 8 to 2060 respondents. The most frequently studied syndrome was pneumonia (n = 17), followed by acute otitis media (n = 9), meningitis (n = 7) and bacteremia/sepsis (n = 4). Overall, each syndrome was associated with a substantial impact on HSU. Bacteremia/sepsis (range: - 0.331 to 0.992) and meningitis (range: - 0.330 to 0.977) were generally associated with the lowest HSU, followed by pneumonia (range: - 0.054 to 0.998) and acute otitis media (range: 0.064 to 0.970). HSU estimates varied considerably by treatment setting, elicitation method and type of respondent. The only study to compare pneumococcal infections to non-pneumococcal infections in the same population revealed significantly lower HSU estimates among pneumococcal infections. CONCLUSIONS: Pneumococcal syndromes are associated with decreased HSU estimates. Given the considerable heterogeneity in methods and source populations as well as study quality, care should be taken to select the most appropriate estimates.
PURPOSE: Streptococcus pneumoniae infections remain a significant source of morbidity and mortality worldwide. The purpose of this review was to summarize the impact of pneumococcal disease on health state utilities (HSU) in the acute phase of illness. METHODS: We searched MEDLINE, EMBASE, EconLit, the Health Technology Assessment Database, the National Health Economic Evaluation Database, and Tufts Cost-Effectiveness Registry (up to January 2020) for primary studies. Eligible studies elicited HSU estimates using preference-based instruments for the acute phase of infection of pneumococcal syndromes including acute otitis media, pneumonia/lower respiratory tract infections, bacteremia/sepsis, and meningitis. Two reviewers independently conducted screening, data extraction and quality appraisal. RESULTS: We screened 10,178 studies, of which 26 met our inclusion criteria. Cohort sizes ranged from 8 to 2060 respondents. The most frequently studied syndrome was pneumonia (n = 17), followed by acute otitis media (n = 9), meningitis (n = 7) and bacteremia/sepsis (n = 4). Overall, each syndrome was associated with a substantial impact on HSU. Bacteremia/sepsis (range: - 0.331 to 0.992) and meningitis (range: - 0.330 to 0.977) were generally associated with the lowest HSU, followed by pneumonia (range: - 0.054 to 0.998) and acute otitis media (range: 0.064 to 0.970). HSU estimates varied considerably by treatment setting, elicitation method and type of respondent. The only study to compare pneumococcal infections to non-pneumococcal infections in the same population revealed significantly lower HSU estimates among pneumococcal infections. CONCLUSIONS: Pneumococcal syndromes are associated with decreased HSU estimates. Given the considerable heterogeneity in methods and source populations as well as study quality, care should be taken to select the most appropriate estimates.
Keywords:
Bacteremia; Health state utilities; Health-related quality of life; Meningitis; Otitis media; Pneumococcal disease; Pneumonia; Quality of life; Streptococcus pneumoniae
Authors: Carole N M Brouwer; A Rianne Maillé; Maroeska M Rovers; Diederick E Grobbee; Elisabeth A M Sanders; Anne G M Schilder Journal: Int J Pediatr Otorhinolaryngol Date: 2005-04-20 Impact factor: 1.675
Authors: Bradford D Winters; Michael Eberlein; Janice Leung; Dale M Needham; Peter J Pronovost; Jonathan E Sevransky Journal: Crit Care Med Date: 2010-05 Impact factor: 7.598
Authors: Xianding Deng; Deirdre Church; Otto G Vanderkooi; Donald E Low; Dylan R Pillai Journal: Expert Rev Anti Infect Ther Date: 2013-08 Impact factor: 5.091
Authors: Derek Weycker; Raymond A Farkouh; David R Strutton; John Edelsberg; Kimberly M Shea; Stephen I Pelton Journal: BMC Health Serv Res Date: 2016-05-13 Impact factor: 2.655
Authors: Brian Wahl; Katherine L O'Brien; Adena Greenbaum; Anwesha Majumder; Li Liu; Yue Chu; Ivana Lukšić; Harish Nair; David A McAllister; Harry Campbell; Igor Rudan; Robert Black; Maria Deloria Knoll Journal: Lancet Glob Health Date: 2018-07 Impact factor: 26.763